Learning from an epidemiological, population‐based study on prescribed medicine use in adults

Eckert, Kerena; Shi, Zumin; Taylor, Anne; Wittert, Gary; Price, Kay; Goldney, Robert D.

doi:10.1002/pds.3380

Cited by 8 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 An Australian study proposed that if the average number of medications taken per person could be reduced by one, an annual cost saving of $463 million would result. 16 Given the high prevalence of IMU, such reductions in medication use, and therefore cost savings, may not be as farfetched as they first seem. Additional cost benefits of deprescribing may be achieved through reduction in ADRs and, consequently, less use of health services.…”

Section: Other Benefitsmentioning

confidence: 99%

The benefits and harms of deprescribing

Reeve

Shakib

Hendrix

et al. 2014

Medical Journal of Australia

View full text Add to dashboard Cite

Deprescribing is the process of trial withdrawal of inappropriate medications. Currently, the strongest evidence for benefit of deprescribing is from cohort and observational studies of withdrawal of specific medication classes that have shown better patient outcomes, mainly through resolution of adverse drug reactions. Additional potential benefits of deprescribing include reduced financial costs and improved adherence with other medications. The harms of ceasing medication use include adverse drug withdrawal reactions, pharmacokinetic and pharmacodynamic changes and return of the medical condition. These can be minimised with proper planning (ie, tapering), monitoring after withdrawal, and reinitiation of the medication if the condition returns. More evidence is needed regarding negative, non-reversible effects of ceasing use of certain classes of medication, such as acetylcholinesterase inhibitors. Cessation of use has not been studied for many medication classes, and large-scale randomised controlled trials of systematic deprescribing are required before the true benefits and harms can be known.

show abstract

Section: Other Benefitsmentioning

confidence: 99%

The benefits and harms of deprescribing

Reeve

Shakib

Hendrix

et al. 2014

Medical Journal of Australia

View full text Add to dashboard Cite

show abstract

“…Other important benefits to deprescribing include improvement in patients’ overall medication adherence , and a marked reduction in financial costs. An Australian study proposed that if the average number of medications taken per person could be reduced by one, an annual cost saving of $463 million would result .…”

Section: Introductionmentioning

confidence: 99%

“…The present study reports on the qualitative data collected from the hypothetical patient profile used. In this study, we defined preventive medicines as any medicines that are used to delay the progression of an asymptomatic or presymptomatic disease, to symptomatic . Symptomatic treatment was defined as any medicine which reduces or treats the symptoms of a disease rather than its cause or aetiology, to provide comfort to the patient .…”

Section: Introductionmentioning

confidence: 99%

General practitioners’ insight into deprescribing for the multimorbid older individual: a qualitative study

et al. 2016

View full text Add to dashboard Cite

Gaining an insight into GPs' current prescribing patterns is important in designing any interventions aimed at reducing inappropriate prescribing. This study highlights the lack of clarity around deprescribing in multimorbidity. The participants' individual responses varied considerably. Deprescribing guidelines may help to clarify evidence based medicine relating to controversial areas and could hence decrease this variation.

show abstract

“…An Australian study projected that if the average number of medications taken per person could be reduced by one; this would result in an annual cost-saving of $463 million dollars. 8 Deprescribing has been shown to produce positive health outcomes for older people. 3–6 However, the best approach to implement this intervention is not yet clear.…”

Section: Introductionmentioning

confidence: 99%

Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT-polypharmacy) in residential aged care facilities

2017

View full text Add to dashboard Cite

IntroductionTargeted deprescribing of anticholinergic and sedative medicines can lead to positive health outcomes in older people; as they have been associated with cognitive and physical functioning decline. This study will examine whether the proposed intervention is feasible at reducing the prescription of anticholinergic and sedative medicines in older people.Methods and analysisThe Standard Protocol Items: Recommendations for Interventional trials (SPIRIT checklist) was used to develop and report the protocol. Single group (precomparison and postcomparison) feasibility study design.Study population3 residential care homes have been recruited.InterventionThis will involve a New Zealand registered pharmacist using peer-reviewed deprescribing guidelines, to recommend to general practitioners (GPs), sedative and anticholinergic medicines that can be deprescribed. The cumulative use of anticholinergic and sedative medicines for each participant will be quantified, using the Drug Burden Index (DBI).OutcomesThe primary outcome will be the change in the participants' DBI total and DBI PRN 3 and 6 months after implementing the deprescribing intervention. Secondary outcomes will include the number of recommendations taken up by the GP, participants' cognitive functioning, depression, quality of life, activities of daily living and number of falls.Data collection pointsParticipants' demographic and clinical data will be collected at the time of enrolment, along with the DBI. Outcome measures will be collected at the time of enrolment, 3 and 6 months' postenrolment.Ethics and disseminationEthics approval has been granted by the Human Disability and Ethics Committee. Ethical approval number (16/NTA/61).Trial registration numberPre-results; ACTRN12616000721404.

show abstract

Learning from an epidemiological, population‐based study on prescribed medicine use in adults

Cited by 8 publications

References 15 publications

The benefits and harms of deprescribing

The benefits and harms of deprescribing

General practitioners’ insight into deprescribing for the multimorbid older individual: a qualitative study

Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT-polypharmacy) in residential aged care facilities

Contact Info

Product

Resources

About